TCW Group Inc. trimmed its position in Celgene Co. (NASDAQ:CELG) by 2.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,606,002 shares of the biopharmaceutical company’s stock after selling 41,310 shares during the period. Celgene comprises about 1.9% of TCW Group Inc.’s portfolio, making the stock its 9th largest holding. TCW Group Inc.’s holdings in Celgene were worth $234,188,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the stock. Arcadia Investment Management Corp MI boosted its holdings in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the last quarter. Thompson Davis & CO. Inc. boosted its holdings in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the last quarter. Guidant Wealth Advisors acquired a new position in shares of Celgene during the 3rd quarter worth approximately $119,000. Motco boosted its holdings in shares of Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the last quarter. Finally, Balentine LLC boosted its holdings in shares of Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 481 shares during the last quarter. Institutional investors own 79.74% of the company’s stock.
CELG has been the topic of several recent research reports. Royal Bank of Canada lowered their target price on Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a report on Friday, October 27th. Leerink Swann restated a “buy” rating and set a $156.00 target price on shares of Celgene in a report on Friday, October 20th. Morgan Stanley lowered their target price on Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a report on Monday, October 23rd. SunTrust Banks lowered their target price on Celgene from $156.00 to $127.00 and set a “buy” rating on the stock in a report on Friday, October 27th. Finally, William Blair restated an “outperform” rating on shares of Celgene in a report on Friday, October 20th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have given a buy rating to the stock. Celgene has an average rating of “Buy” and a consensus target price of $131.18.
Celgene Co. (CELG) opened at $106.00 on Friday. The company has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.58 earnings per share. sell-side analysts forecast that Celgene Co. will post 6.68 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was reported by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.thestockobserver.com/2018/01/13/tcw-group-inc-has-234-19-million-position-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.